Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Indonesian Journal of Medicine Acta Neurologica Indonesia
Chandra Kusuma, Hendrawan
Unknown Affiliation
Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Septic Shock and Multi-Organ Dysfunction Syndrome in a Patient with Extensive Tophaceous Gout, Diagnostic and Management Challenges in South Papua: A Case Report Chandra Kusuma, Hendrawan; Sri Rejeki, Ni Made Darma Parni; Sitorus, Pamela Yacinta
Indonesian Journal of Medicine Vol. 10 No. 2 (2025)
Publisher : Masters Program in Public Health, Sebelas Maret University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26911/theijmed.2025.10.2.824

Abstract

Introduction: Septic shock and multiple organ dysfunction syndrome (MODS) are interrelated medical conditions arising from the body's response to severe infection. Extensive tophaceous gout is recognized for its potential to worsen kidney failure, thereby negatively impacting the prognosis of patients suffering from septic shock and MODS. Case presentation: This case report describes a male patient in his 40s who presented to the emergency department in an unresponsive state and was diagnosed with septic shock, likely secondary to pneumonia, which progressed to MODS. The patient also had uncontrolled hyperuricemia, resulting in extensive tophaceous gout that may have contributed to renal failure. Despite receiving appropriate fluid resuscitation, vasopressors, and antibiotics, the patient succumbed to severe complications. Key challenges in managing this case included limited diagnostic resources, low health awareness, and unclear health insurance coverage, particularly in the context of medical care in South Papua, Indonesia. Results: The case illustrates the interplay between chronic gout and acute infection. Hyperuricemia may contribute to renal impairment, weaken immune defenses, and worsen outcomes in septic patients—challenges in health access, diagnostics, and patient awareness further complicated management. Conclusion: Our case report emphasizes the possible contribution of unmanaged gout to the deterioration of septic shock, leading to MODS.
Evaluating Brivaracetam As An Adjunctive Therapy For Refractory Focal Onset Seizure: A Meta-Analysis Chandra Kusuma, Hendrawan; Isadora, Eugenia; Putra, Aditya; Kurniawan Sindaka, Jonathan
Acta Neurologica Indonesia Vol. 3 No. 03 (2025): Acta Neurologica Indonesia
Publisher : Departemen Neurologi Fakultas Kedokteran Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69868/ani.v3i03.70

Abstract

Background: This study evaluated the safety, tolerability and effectiveness of Brivaracetam (BRV) as an adjunctive therapy for managing focal-onset seizures that are uncontrolled by primary antiseizure medications (ASMs). Method: This review systematically incorporated studies from databases including PubMed, ProQuest, The Lancet, EBSCO and the Cochrane Library. Study quality was assessed using the Cochrane Risk of Bias 2 tool. Meta-analysis was conducted with Review Manager 5.4. Result: Seven studies were included, with five qualifying for meta-analysis involving 2,486 patients taking BRV alongside one or more AEDs. The pooled risk ratios for a 50% reduction in seizure frequency and complete seizure freedom were 1.83 (95% confidence interval of 1.60 to 2.08) and 7.52 (95% confidence interval of 3.59 to 15.75), respectively. In terms of safety, the use of adjunctive BRV was linked to significantly higher rates of somnolence (p<0.00001), dizziness (p=0.0001), and fatigue (p=0.0002), along with other drug-related treatment-emergent adverse effects (TEAEs) such as headache, irritability and nausea. There was no significant difference (p>0.05) between the two groups regarding serious adverse effects (SAEs) or the number of patients who withdrew from the study due to drug-related TEAEs or SAEs. Discussion: Adjunctive BRV (50-200 mg daily) notably enhanced efficacy outcomes compared to placebo. While mild to moderate side effects occurred, there were no significant differences in SAEs and withdrawal rate, indicating a favorable safety and tolerability profile that aligns with other adjunctive ASMs. Conclusion: BRV (50–200 mg) is favourable adjunctive therapy for uncontrolled focal-onset seizures.
Co-Authors Aditya Putra, Aditya Isadora, Eugenia Kurniawan Sindaka, Jonathan Sitorus, Pamela Yacinta Sri Rejeki, Ni Made Darma Parni